Pulmonx Corp. (LUNG)

Q: What's priced into Pulmonx Corp. (LUNG) stock?

The valuation signal is mixed: LUNG is tagged as cheap versus peers, while a separate measure shows a 33% premium to peers. Model confidence is low, and the negative expectations-gap reading suggests expectations may already be demanding, so the evidence does not support a clear valuation conclusion.

Q: What does the Pulmonx Corp. (LUNG) outlook hinge on?

Over the next few quarters, the thesis depends on revenue returning to year-over-year growth while gross margins stay near management’s 2026 goal and operating expenses continue to decline. Weaker jobs data or a guidance cut would add pressure, while continued strength from healthcare bellwethers could support the sector backdrop.

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$1.83-2.66%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Pulmonx Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	25.28M
EPS	—	-0.213
FY 2026 · Annual
Revenue	$90M–$92M	90.54M
EPS	—	-1.02
Gross margin	About 76%	—
Operating expenses	$109M–$111M	—
FY 2027 · Annual
Revenue	—	98.33M
EPS	—	-0.942

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain gross margin at 75% for 2026	Pulmonx aims to keep its gross margin at 75% in 2026.	Intact	Gross margin falls below 70% in FY26	Gross margin: 77.97% FY2026-Q2; GAAP. Published target: 75%. Target period is not explicitly aligned with this observation. Source published Aug 4, 202677.966251 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 75c0c4c5-3922-4600-b5c6-8577dcc0e916. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Keep operating expenses under $115M for 2026	A primary condition in Pulmonx Corp.'s published investment case. The stated target is <= $115M.	Intact	Operating expenses exceed $120M in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue between $90M and $92M in 2026	A primary condition in Pulmonx Corp.'s published investment case. The stated target is $90M to $92M.	Intact	Revenue falls below $85M in FY26	Revenue: $22.756M FY2026-Q2; GAAP. Published target: $90M to $92M. Target period is not explicitly aligned with this observation. Source published Aug 4, 202622,756,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 75c0c4c5-3922-4600-b5c6-8577dcc0e916. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-1.04 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.10B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.04	$98,072,000	5 / 5
2026-07-25	$-1.04	$98,072,000	5 / 5
2026-07-26	$-1.04	$98,072,000	5 / 5
2026-07-27	Unavailable	Unavailable	4 / 4
2026-07-28	Unavailable	Unavailable	4 / 4
2026-07-29	Unavailable	Unavailable	4 / 4
2026-07-30	$-1.04	$98,072,000	5 / 5
2026-07-31	$-0.97	$97,934,200	5 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	$-0.96	$98,314,200	5 / 5
2026-08-03	$-0.94	$98,314,200	5 / 5
2026-08-04	$-0.94	$98,314,200	5 / 5
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-07	Unavailable	Unavailable	4 / 4
2026-08-08	$-0.94	$98,314,200	5 / 5
2026-08-09	$-0.94	$98,314,200	5 / 5
2026-08-10	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	4 / 4
2026-08-13	$-0.94	$98,314,200	5 / 5
2026-08-14	Unavailable	Unavailable	4 / 4
2026-08-15	Unavailable	Unavailable	4 / 4
2026-08-16	Unavailable	Unavailable	4 / 4
2026-08-17	Unavailable	Unavailable	4 / 4
2026-08-18	Unavailable	Unavailable	4 / 4
2026-08-19	Unavailable	Unavailable	4 / 4
2026-08-20	Unavailable	Unavailable	4 / 4
2026-08-21	Unavailable	Unavailable	4 / 4
2026-08-22	Unavailable	Unavailable	4 / 4
2026-08-23	Unavailable	Unavailable	4 / 4
2026-08-24	Unavailable	Unavailable	4 / 4
2026-08-25	Unavailable	Unavailable	4 / 4
2026-08-26	Unavailable	Unavailable	4 / 4
2026-08-27	Unavailable	Unavailable	4 / 4
2026-08-28	Unavailable	Unavailable	4 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	2
2026-06-01	4	2
2026-07-01	3	2
2026-08-01	3	2
2026-09-01	3	2
2026-10-01	3	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain gross margin at 75% for 2026Gross margin: 77.97%
Keep operating expenses under $115M for 2026Direct metric needs a verified mapping
Achieve revenue between $90M and $92M in 2026Revenue: $22.756M

Next proof point

Oct 27, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-55.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Pulmonx Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making healthcare business with a potential improvement story, not an established earnings compounder. The multi-year view is intact, supported by recent earnings beats and stronger sector conditions, but revenue growth has not yet returned.

What's priced into Pulmonx Corp.

The valuation signal is mixed: LUNG is tagged as cheap versus peers, while a separate measure shows a 33% premium to peers. Model confidence is low, and the negative expectations-gap reading suggests expectations may already be demanding, so the evidence does not support a clear valuation conclusion.

What the fundamentals likely do

Near term, better gross margins and lower operating expenses show progress, but revenue fell year over year in both reported 2026 quarters. Management says it is focused on returning to revenue growth, though recent results show limited progress; the next guidance update is a key risk.

What Pulmonx Corp. hinges on

Over the next few quarters, the thesis depends on revenue returning to year-over-year growth while gross margins stay near management’s 2026 goal and operating expenses continue to decline. Weaker jobs data or a guidance cut would add pressure, while continued strength from healthcare bellwethers could support the sector backdrop.

Bottom line

For the 1-3 year view, LUNG has signs of operating improvement, but the business remains loss-making and revenue growth is unproven. The thesis is intact, with execution and the broader healthcare backdrop as the main swing factors. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	25.28M
EPS	—	-0.213
FY 2026 · Annual
Revenue	$90M–$92M	90.54M
EPS	—	-1.02
Gross margin	About 76%	—
Operating expenses	$109M–$111M	—
FY 2027 · Annual
Revenue	—	98.33M
EPS	—	-0.942

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-1.04 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.10B → Unavailable · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.04	$98,072,000	5 / 5
2026-07-25	$-1.04	$98,072,000	5 / 5
2026-07-26	$-1.04	$98,072,000	5 / 5
2026-07-27	Unavailable	Unavailable	4 / 4
2026-07-28	Unavailable	Unavailable	4 / 4
2026-07-29	Unavailable	Unavailable	4 / 4
2026-07-30	$-1.04	$98,072,000	5 / 5
2026-07-31	$-0.97	$97,934,200	5 / 5
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	$-0.96	$98,314,200	5 / 5
2026-08-03	$-0.94	$98,314,200	5 / 5
2026-08-04	$-0.94	$98,314,200	5 / 5
2026-08-05	Unavailable	Unavailable	4 / 4
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-07	Unavailable	Unavailable	4 / 4
2026-08-08	$-0.94	$98,314,200	5 / 5
2026-08-09	$-0.94	$98,314,200	5 / 5
2026-08-10	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	4 / 4
2026-08-13	$-0.94	$98,314,200	5 / 5
2026-08-14	Unavailable	Unavailable	4 / 4
2026-08-15	Unavailable	Unavailable	4 / 4
2026-08-16	Unavailable	Unavailable	4 / 4
2026-08-17	Unavailable	Unavailable	4 / 4
2026-08-18	Unavailable	Unavailable	4 / 4
2026-08-19	Unavailable	Unavailable	4 / 4
2026-08-20	Unavailable	Unavailable	4 / 4
2026-08-21	Unavailable	Unavailable	4 / 4
2026-08-22	Unavailable	Unavailable	4 / 4
2026-08-23	Unavailable	Unavailable	4 / 4
2026-08-24	Unavailable	Unavailable	4 / 4
2026-08-25	Unavailable	Unavailable	4 / 4
2026-08-26	Unavailable	Unavailable	4 / 4
2026-08-27	Unavailable	Unavailable	4 / 4
2026-08-28	Unavailable	Unavailable	4 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings